| __timestamp | Celldex Therapeutics, Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 3004000 |
| Thursday, January 1, 2015 | 4011000 | 26972000 |
| Friday, January 1, 2016 | 102026000 | 58187000 |
| Sunday, January 1, 2017 | 96171000 | 79479000 |
| Monday, January 1, 2018 | 66449000 | 94123000 |
| Tuesday, January 1, 2019 | 42672000 | 114249000 |
| Wednesday, January 1, 2020 | 42534000 | 131328000 |
| Friday, January 1, 2021 | 3068000 | 150991000 |
| Saturday, January 1, 2022 | 1400000 | 206997000 |
| Sunday, January 1, 2023 | 3008000 | 255000000 |
| Monday, January 1, 2024 | 312068000 |
Unleashing insights
In the ever-evolving landscape of biotechnology, understanding cost dynamics is crucial. This analysis delves into the cost of revenue trends for Incyte Corporation and Celldex Therapeutics, Inc. over the past decade. From 2014 to 2023, Incyte Corporation has seen a staggering increase in its cost of revenue, growing by over 8,400%, from a modest $3 million in 2014 to a substantial $255 million in 2023. This reflects Incyte's aggressive expansion and investment in research and development.
Conversely, Celldex Therapeutics, Inc. experienced a more volatile journey. Starting at $102 million in 2014, their cost of revenue plummeted to just $3 million by 2023, a dramatic 97% decrease. This shift may indicate strategic pivots or operational efficiencies. These contrasting trends highlight the diverse strategies within the biotech sector, offering valuable insights for investors and industry analysts alike.
Cost of Revenue Trends: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Regeneron Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Incyte Corporation and ACADIA Pharmaceuticals Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Dyne Therapeutics, Inc.
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Veracyte, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: MorphoSys AG vs Celldex Therapeutics, Inc.